INmune Bio Inc. Announces New Preclinical Data at AACR 2026 Demonstrating INB03 (XPro1595) Overcomes Resistance and Reduces Metastases in HER2-Positive Breast Cancer Models

Go back to INmune Bio Inc. Announces New Preclinical Data at AACR 2026 Demonstrating INB03 (XPro1595) Overcomes Resistance and Reduces Metastases in HER2-Positive Breast Cancer Models
(NASDAQ: INMB) Delayed: 1.43 -0.02 (1.38%)
Previous Close $1.45    52 Week High
Open $1.41    52 Week Low
Day High $1.48    P/E N/A 
Day Low $1.35    EPS
Volume 284,421